The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Arsenyeva A.A.

Samara State Medical University of the Ministry of Health of Russia

Lyamin A.V.

Samara State Medical University

Migacheva N.B.

Samara State Medical University of the Ministry of Health of Russia

Kurmaev D.P.

Samara State Medical University of the Ministry of Health of Russia

Orlov E.V.

Samara State Medical University of the Ministry of Health of Russia

Bulgakova S.V.

Samara State Medical University

Treneva E.V.

Samara State Medical University

Historical aspects and prospects of psoriasis treatment

Authors:

Arsenyeva A.A., Lyamin A.V., Migacheva N.B., Kurmaev D.P., Orlov E.V., Bulgakova S.V., Treneva E.V.

More about the authors

Read: 1325 times


To cite this article:

Arsenyeva AA, Lyamin AV, Migacheva NB, Kurmaev DP, Orlov EV, Bulgakova SV, Treneva EV. Historical aspects and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Venereology. 2025;24(3):284‑292. (In Russ.)
https://doi.org/10.17116/klinderma202524031284

Recommended articles:
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Search of diagnostic and prognostic biomarkers of immu­noinflammatory dermatoses by means of flow cyto­metry. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):170-177
Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xero­sis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):178-184
Key specific tools for asse­ssment of life quality of patients with psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):319-325
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
New approach to clinical evaluation of nail lesions in psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):453-460
Adhe­rence of patients to acne therapy using systemic isotretinoin. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):483-488

References:

  1. Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170-173.  https://doi.org/10.7861/clinmed.2021-0257
  2. Olejnik M, Adamski Z, Dorocka-Bobkowska B. Psoriasis: From antiquity to the present. Indian J Dermatol Venereol Leprol. 2023;89(1):149-153.  https://doi.org/10.25259/IJDVL_1200_2021
  3. Pereverzina NO, Kruglova LS, Korotaeva TV, Lila AM. Systematic review and meta-analysis: risk factors for psoriatic arthritis. Part 2. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(2):26-33. (In Russ.). https://doi.org/10.14412/1996-7012-2022-2-26-33
  4. Boehncke WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 2018;9:579. Published 2018 Apr 5.  https://doi.org/10.3389/fimmu.2018.00579
  5. Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Similarities and differences. Joint Bone Spine. 2023;90(1):105469. https://doi.org/10.1016/j.jbspin.2022.105469
  6. Dascălu RC, Bărbulescu AL, Stoica LE, et al. Review: A Contemporary, Multifaced Insight into Psoriasis Pathogenesis. J Pers Med. 2024;14(5):535. Published 2024 May 16.  https://doi.org/10.3390/jpm14050535
  7. Alexander H, Nestle FO. Pathogenesis and immunotherapy in cutaneous psoriasis: what can rheumatologists learn? Curr Opin Rheumatol. 2017; 29(1):71-78.  https://doi.org/10.1097/BOR.0000000000000358
  8. Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200-e207. https://doi.org/10.1016/S2665-9913(23)00034-6
  9. Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. Published 2020 May 28.  https://doi.org/10.1136/bmj.m1590
  10. Kubanov AA, Bogdanova EV. Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010–2019. Vestnik dermatologii I cosmetologii. 2020;96(5):7-18. (In Russ.). https://doi.org/10.25208/vdv1171-2020-96-5-07-18
  11. Mohd Noor AA, Azlan M, Mohd Redzwan N. Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action. Biomedicines. 2022;10(2):498. Published 2022 Feb 20.  https://doi.org/10.3390/biomedicines10020498
  12. Otero ME, van Geel MJ, Hendriks JC, van de Kerkhof PC, Seyger MM, de Jong EM. A pilot study on the Psoriasis Area and Severity Index (PASI) for small areas: Presentation and implications of the Low PASI score. J Dermatolog Treat. 2015;26(4):314-317.  https://doi.org/10.3109/09546634.2014.972316
  13. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. Published 2019 Mar 23.  https://doi.org/10.3390/ijms20061475
  14. Zhukova OV, Kruglova LS, Sharapova EN. Combined ultraviolet therapy and methotrexate in treatment of patients with severe forms of psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2015;(2):66-72. (In Russ.). https://doi.org/10.17116/klinderma201514266-72
  15. Reid C, Griffiths CEM. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm Venereol. 2020;100(3):adv00032. Published 2020 Jan 30.  https://doi.org/10.2340/00015555-3386
  16. Alderson HE. Heliotherapy for psoriasis. Arch Dermatol. 1923;8:79-80. 
  17. Goeckerman WH. Treatment of psoriasis. Northwest Med. 1925;24:229. 
  18. Ingram JT. The approach to psoriasis. Br Med J. 1953;2(4836):591-594.  https://doi.org/10.1136/bmj.2.4836.591
  19. Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952;19(2):101-102.  https://doi.org/10.1038/jid.1952.72
  20. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci. 1951;221(2):176-182. 
  21. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm. 1958;78(2):200-203.  https://doi.org/10.1001/archderm.1958.01560080060010
  22. Warren RB, Weatherhead SC, Smith CH, et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2017 Jun;176(6):1678. https://doi.org/10.1111/bjd.14816
  23. Schweckendiek W. [Treatment of psoriasis vulgaris] Heilung von Psoriasis vulgaris. Med Monatsschr. 1959;13(2):103-104. 
  24. Tronnier H, Schüle D. Zur dermatologischen Therapie von Dermatosen mit langwelligem UV nach Photosensibilisierung der Haut mit Methoxsalen. Erste Ergebnisse bei der Psoriasis vulgaris [Dermatological therapy of dermatoses using long-wave UV following methoxsalen photosensitization of the skin. First results in psoriasis vulgaris]. Z Haut Geschlechtskr. 1973;48(10): 385-393. 
  25. Parrish JA, Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol. 1981;76(5):359-362.  https://doi.org/10.1111/1523-1747.ep12520022
  26. Walters IB, Burack LH, Coven TR, Gilleaudeau P, Krueger JG. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol. 1999;40(6 Pt 1):893-900.  https://doi.org/10.1016/s0190-9622(99)70076-9
  27. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301(10):555.  https://doi.org/10.1056/NEJM197909063011016
  28. Baker BS, Swain AF, Valdimarsson H, Fry L. T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol. 1984;110(1):37-44.  https://doi.org/10.1111/j.1365-2133.1984.tb07309.x
  29. Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed). 1986;293(6549):731-732.  https://doi.org/10.1136/bmj.293.6549.731
  30. Berth-Jones J, Exton LS, Ladoyanni E, et al. British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018. Br J Dermatol. 2019;180(6):1312-1338. https://doi.org/10.1111/bjd.17587
  31. Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res. 1990;282(3):164-167.  https://doi.org/10.1007/BF00372616
  32. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol. 1988;37(5):889-895.  https://doi.org/10.1016/0006-2952(88)90177-3
  33. Berth-Jones J, Chu AC, Dodd WA, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol. 1992;127(3):266-271.  https://doi.org/10.1111/j.1365-2133.1992.tb00126.x
  34. Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol. 1994;131(5):673-677.  https://doi.org/10.1111/j.1365-2133.1994.tb04981.x
  35. Zheng ZS, Polakowska R, Johnson A, Goldsmith LA. Transcriptional control of epidermal growth factor receptor by retinoic acid. Cell Growth Differ. 1992;3(4):225-232. 
  36. Bécherel PA, Mossalayi MD, LeGoff L, et al. Mechanism of anti-inflammatory action of retinoids on keratinocytes. Lancet. 1994;344(8936):1570-1571. https://doi.org/10.1016/s0140-6736(94)90377-8
  37. Ormerod AD, Campalani E, Goodfield MJ; BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010;162(5):952-963.  https://doi.org/10.1111/j.1365-2133.2010.09755.x
  38. Sommerburg C, Kietzmann H, Eichelberg D, Goos M, Heese A, Holzle E, et al. Acitretin in combination with PUVA: a randomized double-blind placebo-controlled study in severe psoriasis. J Eur Acad Dermatol Venereol. 1993;2:308-317. 
  39. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.  https://doi.org/10.1159/000250839
  40. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3): 210-216.  https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
  41. Rathod DG, Muneer H, Masood S. Phototherapy. 2023 Feb 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. PMID: 33085287. Accessed Oct 14, 2024.
  42. Campbell J. Safe and effective use of phototherapy and photochemotherapy in the treatment of psoriasis. Br J Nurs. 2020;29(10):547-552.  https://doi.org/10.12968/bjon.2020.29.10.547
  43. Atci T, Baykal C. Efficacy of narrow-band ultraviolet-B therapy in patch-stage mycosis fungoides: A clinical study and review of the literature. Photodermatol Photoimmunol Photomed. 2020;36(4):271-277.  https://doi.org/10.1111/phpp.12547
  44. Ara S, Mowla MR, Alam M, Khan I. Efficacy of oral methotrexate (MTX) monotherapy vs oral MTX plus narrowband ultraviolet light B phototherapy in palmoplantar psoriasis. Dermatol Ther. 2020;33(4):e13486. https://doi.org/10.1111/dth.13486
  45. Fukumoto T, Nishiyama S, Oka M, Nishigori C. Implication of phototherapy for rare comorbidity of psoriasis and pemphigus foliaceus: Case report and review of literature. Dermatol Ther. 2020;33(6):e13889. https://doi.org/10.1111/dth.13889
  46. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008; 158(3):558-566.  https://doi.org/10.1111/j.1365-2133.2007.08315.x
  47. Svechnikova EV, Zhufina SE, Morzhanaeva MA. Clinical case: switching from basic therapy with methotrexate to therapy with netakimab, an IL-17 inhibitor, in a patient with severe psoriasis. Meditsinskiy Sovet. 2023;17(2):69-74. (In Russ.). https://doi.org/10.21518/ms2023-012
  48. Lindqvist T, Salah LA, Gillstedt M, Wennberg AM, Osmancevic A. Methotrexate Management in Psoriasis: Are We Following the Guidelines? Acta Derm Venereol. 2018;98(4):449-451.  https://doi.org/10.2340/00015555-2857
  49. Coates LC, Helliwell PS. Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. J Rheumatol. 2016;43(2):356-361.  https://doi.org/10.3899/jrheum.150614
  50. West J, Ogston S, Berg J, et al. HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment. Clin Exp Dermatol. 2017;42(6):651-655.  https://doi.org/10.1111/ced.13100
  51. Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris — Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281-317.  https://doi.org/10.1111/jdv.16926
  52. van Huizen AM, Menting SP, Gyulai R, et al. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatol. 2024 Feb 1;160(2):241.  https://doi.org/10.1001/jamadermatol.2022.0434
  53. Bishnoi P, Kumari R, Thappa DM. Monitoring methotrexate hepatotoxicity in psoriasis. Indian J Dermatol Venereol Leprol. 2011;77(5):545-548.  https://doi.org/10.4103/0378-6323.84014
  54. Bellinato F, Maurelli M, Geat D, Girolomoni G, Gisondi P. Managing the Patient with Psoriasis and Metabolic Comorbidities. Am J Clin Dermatol. 2024;25(4):527-540.  https://doi.org/10.1007/s40257-024-00857-0
  55. Michalska-Bańkowska A, Grabarek B, Wcisło-Dziadecka D, Gola J. The impact of diabetes and metabolic syndromes to the effectiveness of cyclosporine a pharmacotherapy in psoriatic patients. Dermatol Ther. 2019;32(3): e12881. https://doi.org/10.1111/dth.12881
  56. Zolota A, Miserlis G, Solonaki F, et al. New-Onset Diabetes After Transplantation: Comparison Between a Cyclosporine-Based and a Tacrolimus-Based Immunosuppressive Regimen. Transplant Proc. 2018;50(10):3386-3391. https://doi.org/10.1016/j.transproceed.2018.08.037
  57. Lee JH, Youn JI, Kim TY, et al. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis. BMC Dermatol. 2016;16(1):11. Published 2016 Jul 25.  https://doi.org/10.1186/s12895-016-0048-z
  58. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842-855.  https://doi.org/10.1111/j.1476-5381.2009.00559.x
  59. Yilmaz O, Pinto JP, Torres T. New and emerging oral therapies for psoriasis. Drugs Context. 2024 Aug 1;13:2024-5-6.  https://doi.org/10.7573/dic.2024-5-6
  60. National Library of Medicine. A study to evaluate efficacy and safety of SAR441566 in adults with plaque psoriasis (SPECIFI-PSO). Accessed April 23, 2024.
  61. National Library of Medicine. A study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. Accessed April 22, 2024.
  62. National Library of Medicine. A study to evaluate safety, tolerability of LY4100511 (DC-853) in healthy Asian and non-Asian participants. Accessed May 21, 2024.
  63. National Library of Medicine. A single and multiple ascending-dose trial of LEO 153339 in healthy adults. Accessed April 22, 2024. https://clinicaltrials.gov/study/NCT04883333
  64. National Library of Medicine. A study of JNJ-77242113 in adolescent and adult participants with moderate to severe plaque psoriasis (ICONIC- LEAD). Accessed April 23, 2024. https://clinicaltrials.gov/study/NCT06095115
  65. National Library of Medicine. A study of JNJ-77242113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet) (ICONIC-TOTAL). Accessed April 23, 2024.
  66. Shafieva IA, Bulgakova SV, Kurmaev DP, Treneva EV. Use of tofacitinib in psoriatic arthritis (literature review). Meditsinskiy Sovet. 2024;18(12):114-122. (In Russ.). https://doi.org/10.21518/ms2024-230
  67. Chandran V, Malkov VA, Ito KL, et al. Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial. RMD Open. 2023;9(4):e003550. https://doi.org/10.1136/rmdopen-2023-003550
  68. Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis Rheumatol. 2023;75(8): 1370-1380. https://doi.org/10.1002/art.42519
  69. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023; 88(1):40-51.  https://doi.org/10.1016/j.jaad.2022.08.061

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.